WO1997015555A3 - Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren - Google Patents

Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren Download PDF

Info

Publication number
WO1997015555A3
WO1997015555A3 PCT/DE1996/002079 DE9602079W WO9715555A3 WO 1997015555 A3 WO1997015555 A3 WO 1997015555A3 DE 9602079 W DE9602079 W DE 9602079W WO 9715555 A3 WO9715555 A3 WO 9715555A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitrogen monoxide
imidazole derivatives
synthase inhibitors
monoxide synthase
inhibitors
Prior art date
Application number
PCT/DE1996/002079
Other languages
English (en)
French (fr)
Other versions
WO1997015555A2 (de
Inventor
Peter Hoelscher
Hartmut Rehwinkel
Gerardine Burton
Gary Phillips
John Parkinson
Original Assignee
Schering Ag
Peter Hoelscher
Hartmut Rehwinkel
Gerardine Burton
Gary Phillips
John Parkinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Peter Hoelscher, Hartmut Rehwinkel, Gerardine Burton, Gary Phillips, John Parkinson filed Critical Schering Ag
Priority to JP9516208A priority Critical patent/JPH11515008A/ja
Priority to AU13009/97A priority patent/AU1300997A/en
Priority to EP96944573A priority patent/EP0857171A2/de
Publication of WO1997015555A2 publication Critical patent/WO1997015555A2/de
Publication of WO1997015555A3 publication Critical patent/WO1997015555A3/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die Erfindung betrifft die Verbindungen der Formel (I), deren Herstellung und Verwendung in Arzneimitteln.
PCT/DE1996/002079 1995-10-25 1996-10-24 Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren WO1997015555A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9516208A JPH11515008A (ja) 1995-10-25 1996-10-24 イミダゾール誘導体及びその一酸化窒素合成酵素阻害剤としての使用
AU13009/97A AU1300997A (en) 1995-10-25 1996-10-24 Imidazole derivatives and the use thereof as nitrogen monoxide synthase inhibitors
EP96944573A EP0857171A2 (de) 1995-10-25 1996-10-24 Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19541146.3 1995-10-25
DE19541146A DE19541146A1 (de) 1995-10-25 1995-10-25 Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren

Publications (2)

Publication Number Publication Date
WO1997015555A2 WO1997015555A2 (de) 1997-05-01
WO1997015555A3 true WO1997015555A3 (de) 1997-07-10

Family

ID=7776625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1996/002079 WO1997015555A2 (de) 1995-10-25 1996-10-24 Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren

Country Status (7)

Country Link
EP (1) EP0857171A2 (de)
JP (1) JPH11515008A (de)
AU (1) AU1300997A (de)
CA (1) CA2235621A1 (de)
DE (1) DE19541146A1 (de)
WO (1) WO1997015555A2 (de)
ZA (1) ZA969019B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627310A1 (de) * 1996-06-27 1998-01-02 Schering Ag Imidazolderivate als Stickstoffmonoxid-Synthase-Inhibitoren
PT839810E (pt) 1996-11-04 2003-01-31 Bayer Cropscience Sa 1-poliarilpirazois como pesticidas
CZ20014203A3 (cs) * 1999-05-25 2002-06-12 Mitsubishi Pharma Corporation Prostředek a způsob podpory exprese glykoproteinu spojeného s myelinem
AUPQ142599A0 (en) * 1999-07-05 1999-07-29 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
US6525051B2 (en) * 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
KR20030017511A (ko) * 2000-06-28 2003-03-03 에스에스 세야쿠 가부시키 가이샤 이미다졸 유도체 또는 그의 염 및 이를 함유하는 의약
EP1178038A1 (de) 2000-08-04 2002-02-06 Aventis Cropscience S.A. Fungizide Phenylamidin Derivative
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
KR20090092832A (ko) 2001-05-11 2009-09-01 바이오비트럼 에이비(피유비엘) 비만, 제 ⅱ 형 당뇨병 및 cns 장애의 치료를 위한 신규한 아릴술폰아미드 화합물
EP1528921A2 (de) * 2002-08-02 2005-05-11 Pharmacia Corporation Methoden zur behandlung und vorbeugung von magen-darm-krankheiten
US7449481B2 (en) 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
US20070123572A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
WO2006060424A2 (en) * 2004-12-01 2006-06-08 Kalypsys, Inc. Inducible nitric oxide synthase dimerization inhibitors
EP1741708A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit ungesättigtem oder zyklischem Linker, und deren Verwendung als Pharmaka
WO2007039578A1 (en) * 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted azabenzophenone compounds
WO2007039580A1 (en) * 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted benzophenone compounds
EP2222639A1 (de) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryle als pde4-inhibitoren zur behandlung von lungen- und herz-kreislauf-erkrankungen
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
EP2448581B1 (de) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutische zusammensetzungen und verfahren zu ihrer verwendung
PL2448582T3 (pl) 2009-06-29 2017-09-29 Agios Pharmaceuticals, Inc. Pochodne chinolino-8-sulfonamidowe mające działanie przeciwnowotworowe
JP5837091B2 (ja) 2010-12-17 2015-12-24 アジオス ファーマシューティカルズ, インコーポレイテッド ピルビン酸キナーゼm2(pkm2)調節剤としての新規n−(4−(アゼチジン−1−カルボニル)フェニル)−(ヘテロ−)アリールスルホンアミド誘導体
US9328077B2 (en) 2010-12-21 2016-05-03 Agios Pharmaceuticals, Inc Bicyclic PKM2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN103764147B (zh) 2011-05-03 2018-05-22 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9206211B2 (en) 2013-04-17 2015-12-08 Massachusetts Institute Of Technology Metathesis catalysts and methods thereof
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技(上海)有限公司 羧酸化合物及其制备方法和用途
MA44392B1 (fr) 2015-06-11 2023-10-31 Agios Pharmaceuticals Inc Procédés d'utilisation d'activateurs de la pyruvate kinase
TWI780281B (zh) * 2017-12-14 2022-10-11 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541109A (en) * 1968-06-25 1970-11-17 Du Pont 1-substituted imidazoles useful in acth reserve assay
FR2267101A1 (de) * 1974-04-11 1975-11-07 Schering Ag
EP0270091A1 (de) * 1986-12-02 1988-06-08 Tanabe Seiyaku Co., Ltd. Imidazol-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Zubereitungen, welche diese enthalten, Verwendung dieser zur Herstellung therapeutisch wirksamer Arzneimittel und Zwischenprodukte, welche beim Herstellungsverfahren entstehen
EP0385850A2 (de) * 1989-03-03 1990-09-05 Laboratoires Upsa Benzimidazol- und Azabenzimidazol-Derivate, Verfahren zu deren Herstellung, Synthese-Zwischenprodukte, diese enthaltende pharmazeutische Zusammensetzungen, verwendbar bei der Behandlung von Herzgefässerkrankungen und duodenalem Ulcus
DE3942475A1 (de) * 1989-12-22 1991-06-27 Basf Ag Substituierte salicylsaeurealkylester und verfahren zu ihrer herstellung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541109A (en) * 1968-06-25 1970-11-17 Du Pont 1-substituted imidazoles useful in acth reserve assay
FR2267101A1 (de) * 1974-04-11 1975-11-07 Schering Ag
EP0270091A1 (de) * 1986-12-02 1988-06-08 Tanabe Seiyaku Co., Ltd. Imidazol-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Zubereitungen, welche diese enthalten, Verwendung dieser zur Herstellung therapeutisch wirksamer Arzneimittel und Zwischenprodukte, welche beim Herstellungsverfahren entstehen
EP0385850A2 (de) * 1989-03-03 1990-09-05 Laboratoires Upsa Benzimidazol- und Azabenzimidazol-Derivate, Verfahren zu deren Herstellung, Synthese-Zwischenprodukte, diese enthaltende pharmazeutische Zusammensetzungen, verwendbar bei der Behandlung von Herzgefässerkrankungen und duodenalem Ulcus
DE3942475A1 (de) * 1989-12-22 1991-06-27 Basf Ag Substituierte salicylsaeurealkylester und verfahren zu ihrer herstellung

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
A. L. JOHNSON ET. AL.: "The Synthesis of 1-Arylimidazoles, a New Class of Steroid Hydroxylation Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 12, no. 6, November 1969 (1969-11-01), WASHINGTON DC, US, pages 1024 - 8, XP000653294 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. 119, no. 2, 1996, pages 423 - 31 *
C. ESCOLASTICO ET. AL.: "Imidazole and Benzimidazole Addition to Quinones. Formation of meso and d,l Isomers and Crystal Structure of the d,l Isomer of 2,3-Bis(benzimidazol-1'-yl)- 1,4-Dihydroxybenzene.", TETRAHEDRON, vol. 50, no. 43, 1994, OXFORD, GB, pages 12489 - 12510, XP000652111 *
CHEMICAL ABSTRACTS, vol. 125, no. 21, 18 November 1996, Columbus, Ohio, US; abstract no. 265016r, R. L. HANDY ET. AL.: "Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole." page 38; column 1; XP002029806 *
D. J. WOLFFE ET. AL.: "Calmodulin-dependent Nitric-oxide Synthase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 13, 5 May 1993 (1993-05-05), ROCKVILLE PIKE, US, pages 9425 - 9, XP000652112 *
D. M. ZIMMERMANN ET. AL.: "Structure-activity Relationships of trans-3,4-Dimethyl-4-(3-hydroxyphenyl)-piperidine Antagonists for mu and kappa-Opioid Receptors.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 20, 1 October 1993 (1993-10-01), WASHINGTON DC, US, pages 2964 - 72, XP002029805 *
D. POORANCHAND ET. AL.: "Reaction of Dimethyl N-aryl and N-alkylcarbonimidodithioates with Aminoacetaldehyde Diethyl Acetal. A Direct Synthesis of 1-Aryl and 1-Alkyl-2-methylthioimidazoles.", SYNTHESIS, no. 12, December 1987 (1987-12-01), STUTTGART, DE, pages 1136 - 8, XP002029808 *
E. L. PLUMMER ET. AL.: "Heterocyclic Analogues of Substituted (1,1'-Biphenyl)-3-methyl pyrethroid Insecticides.", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 32, no. 5, September 1984 (1984-09-01), WASHINGTON DC, US, pages 1116 - 21, XP000653215 *
J. F. K. WILSHIRE: "The Preparation of 2-Fluoro-5-nitrobenzonitrile and the Proton Magnetic Resonance Spectra of some Compounds Containing the N-(2-Cyano-4-nitrophenyl) Group.", AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 20, no. 10, October 1967 (1967-10-01), MELBOURNE, AU, pages 1663 - 70, XP000653236 *
J. F. K. WILSHIRE: "The Preparation of 4-Fluoro-3-nitrobenzonitrile and the Proton Magnetic Resonance Spectra of some Compounds Containing the N-4-Cyano-2-nitrophenyl Group.", AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 20, no. 10, October 1967 (1967-10-01), MELBOURNE, AU, pages 2269 - 73, XP000653235 *
J. OHMORI ET. AL.: "6-(1H-Imidazol-1-yl)-7-nitro-2,3-(1H,4H) quinoxazolinedione Hydrochloride (YM90K) and Related Compounds. Structure-activity Relationships for the AMPA-Type Non-NMDA Receptor.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 4, 18 February 1994 (1994-02-18), WASHINGTON DC, US, pages 467 - 75, XP002029804 *
J. W. LAMPE ET. AL.: "A Novel Rearangement of 1-(2-Aminoaryl)imidazoles.", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 31, no. 2, March 1994 (1994-03-01), pages 287 - 91, XP000653292 *
P. FRANCHETTI ET. AL.: "Structure-Activity Relationships in Reactions of Organophosphorus Inhibited Acetylcholinesterase. 7. 1-Aryl-2-hydroxyiminomethyl-3-methylimidazolium Iodides.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 17, no. 1, January 1974 (1974-01-01), WASHINGTON DC, US, pages 18 - 22, XP000653251 *
P. STREHLKE: "Antifungale Imidazolverbindungen II. Äther von (1-Imidazolyl)- phenolen.", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, CHIMICA THERAPEUTICA, vol. 14, no. 3, May 1979 (1979-05-01), pages 227 - 30, XP000653317 *
R. G. R. BACON ET. AL.: "Metal Ions and Complexes in Organic Reactions. Part XVIII.", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS I, no. 16, 1974, OXFORD, GB, pages 1970 - 5, XP000653267 *

Also Published As

Publication number Publication date
CA2235621A1 (en) 1997-05-01
EP0857171A2 (de) 1998-08-12
AU1300997A (en) 1997-05-15
DE19541146A1 (de) 1997-04-30
ZA969019B (en) 1997-05-29
WO1997015555A2 (de) 1997-05-01
JPH11515008A (ja) 1999-12-21

Similar Documents

Publication Publication Date Title
WO1997015555A3 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EP1060738A3 (de) Karmin enthaltende selbstbräunende Zusammensetzung
AU4308397A (en) Substituted 2-pyrimidineamines, their preparation and their use as proteine kinase inhibitors
WO2002009713A3 (de) Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
EP0811595A4 (de) Hydrochalconderivate, diese enthaltende kosmetische zubereitungen, und verfahren zur herstellung derselben
CA2349330A1 (en) Nitrogen containing heterobicycles as factor xa inhibitors
EP1037639A4 (de) Heteroaryl-substituierte imidazol-verbindungen, deren pharmazeutische zusammensetzungen und verwendungen
AU6230098A (en) Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
EP1293503A4 (de) Triazol-derivate
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
WO2002008194A8 (de) Acridin-derivate und deren verwendung als arzneimittel
HUP0200623A3 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
AU6989800A (en) Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
HUP0203288A3 (en) Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
WO2001010816A3 (de) Substituierte 2-Dialkylaminoalkylbiphenyl-derivate
HUP0203422A3 (en) Imidazole derivatives as phosphodiesterase vii inhibitors, process for their preparation and pharmaceutical compositions containing them
EP0861238A4 (de) Hexahydro-5-imino-1,4-heteroazepinderivate als inhibitoren von stickstoffoxid-sythase
WO2000039083A3 (en) Pyrazole compounds and uses thereof
HUP9903492A3 (en) Quinoline derivatives as type iv phosphodiesterase inhibitors, process for their preparation, pharmaceutical compositions containing the same and their use
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use
WO2002050067A3 (en) Pharmaceutical heterocyclic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996944573

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2235621

Country of ref document: CA

Ref country code: CA

Ref document number: 2235621

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 516208

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996944573

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97516208

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1996944573

Country of ref document: EP